Current status of lung transplantation in Japan—report from Japanese lung transplant registry

BACKGROUND Lung transplantation recipients (LTx) are more susceptible to severe acute respiratory syndrome-corona virus-2 (SARS-Cov-2) and suffer severer outcomes than healthy subjects. OBJECTIVE Here we aim to analyze whether it was appropriate to maintain lung transplant programs in medical institutions accepting coronavirus disease 2019 (COVID-19) patients. METHODS Methods: the clinical characteristics, laboratory testing, and epidemiology survey results of 10 LTx recipients undergoing allograft lung transplantation surgeries in the First Affiliated Hospital of Zhengzhou University during the COVID-19 pandemic were collected. A web-based epidemiology questionnaire was used to collect the information of LTx recipients after discharge. RESULTS A total of 10 LTx recipients were identified. The main cause of lung transplantation was idiopathic interstitial pneumonia (60%), with another rare case of cystic fibrosis. Comorbidities involved hyperlipidemia, subclinical hyperthyroidism, diabetes, viral hepatitis of type B. The average white blood cell (WBC) count and average lymphocyte count were 9.5±3.9×109 cells/liter and 1.7±1.1×109 cells/liter, respectively. 40% of the LTx recipients had lymphopenia. Impaired alanine aminotransferase (ALT) and aspartate transaminase (AST) were observed in LTx recipients. Good habitats of hand hygiene (100%), wearing protective masks behaviors (100%), indoor ventilation behaviors (100%), indoor disinfection measures (83%), personal tableware (67%), separate room (100%), personal bedsheets/ quilts (100%) and drinking glasses (100%) were observed during the follow-up. None of the LTx recipients or their family members get infected with SARS-CoV-2 during the novel coronavirus pandemic. CONCLUSIONS Under the premise of taking appropriate preventive measures during hospitalization and after discharge, the lung transplant program can be maintained in the medical institution that accepts patients with COVID-19. INTERNATIONAL REGISTERED REPORT RR2-doi: https://doi.org/10.1101/2020.07.06.20147264

Download Full-text

Single Lung Transplant Remains a Viable Alternative to Double Lung Transplantation for the Patients with Severe Secondary Pulmonary Hypertension

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2021.01.1916 ◽

2021 ◽

Vol 40 (4) ◽

pp. S71-S72

Author(s):

G. Sunagawa ◽

H. Kehara ◽

M. Kashem ◽

C. Mangukia ◽

S. Brann ◽

...

Keyword(s):

Pulmonary Hypertension ◽

Lung Transplantation ◽

Lung Transplant ◽

Viable Alternative ◽

Single Lung Transplant ◽

Secondary Pulmonary Hypertension

Download Full-text

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth Adult Heart Transplantation Report — 2021; Focus on Recipient Characteristics

The Journal of Heart and Lung Transplantation ◽

10.1016/j.healun.2021.07.015 ◽

2021 ◽

Author(s):

Kiran K. Khush ◽

Eileen Hsich ◽

Luciano Potena ◽

Wida S. Cherikh ◽

Daniel C. Chambers ◽

...

Keyword(s):

Heart Transplantation ◽

Lung Transplantation ◽

International Society ◽

Organ Transplant ◽

Adult Heart ◽

Transplant Registry ◽

Thoracic Organ

Download Full-text

Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection

AJP Lung Cellular and Molecular Physiology ◽

10.1152/ajplung.00330.2003 ◽

2004 ◽

Vol 286 (6) ◽

pp. L1129-L1139 ◽

Cited By ~ 63

Author(s):

Tina L. Sumpter ◽

David S. Wilkes

Keyword(s):

Lung Transplantation ◽

Lung Transplant ◽

Transplant Rejection ◽

Survival Rates ◽

Definitive Treatment ◽

Solid Organ ◽

Type V Collagen ◽

End Stage ◽

Type V

Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-yr survival rates are worse for the lung than for any other transplanted organ. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen [col(V)], is a target of the rejection response. Col(V) is highly conserved; therefore, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article. In addition, the potential role of regulatory T cells that are crucial to modulating autoimmunity and alloimmunity is also discussed.

Download Full-text